Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 as Monotherapy for Advanced Pancreatic Cancer
January 16, 2025 | 07:03
Innovent Biologics, Inc., announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI343.
Mobile Version